CapsoVision (NASDAQ:CV) Posts Earnings Results

CapsoVision (NASDAQ:CV) posted its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $2.79 million for the quarter.

Here are the key takeaways from CapsoVision’s conference call:

• CapsoVision said underlying utilization remains strong, with deeper engagement in existing accounts and continued growth in end-user consumption of CapsoCam Plus across its installed base.
• The company expects a meaningful near-term catalyst from AI Highlights, its AI-assisted reading feature for CapsoCam Plus, with FDA clearance anticipated around mid-year and a commercial launch shortly after.
• Management highlighted progress across the pipeline, including CapsoCam Colon Gen Two remaining on track for submission in the third quarter of 2026 and enrollment beginning in the pancreatic cancer clinical study.
• First-quarter revenue was $2.8 million, flat year over year, while gross margin declined to 48% from 54% due mainly to tariffs affecting cost of goods sold.
• Operating expenses rose to $8.4 million as the company increased investment in R&D and clinical trials, but CapsoVision ended the quarter with $17.9 million in cash after a $14 million private placement in March.

CapsoVision Stock Down 11.6%

NASDAQ:CV traded down $0.85 during mid-day trading on Friday, reaching $6.45. 124,218 shares of the company were exchanged, compared to its average volume of 114,308. The stock has a market cap of $321.53 million and a PE ratio of -2.95. CapsoVision has a 12 month low of $3.43 and a 12 month high of $15.37. The company has a fifty day moving average of $6.48 and a 200 day moving average of $6.73.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of CapsoVision by 34.1% during the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock valued at $1,649,000 after acquiring an additional 39,231 shares during the period. State Street Corp boosted its stake in CapsoVision by 340.7% in the fourth quarter. State Street Corp now owns 85,929 shares of the company’s stock valued at $919,000 after acquiring an additional 66,429 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of CapsoVision during the 1st quarter valued at $359,000. Citadel Advisors LLC acquired a new position in shares of CapsoVision in the 3rd quarter valued at $115,000. Finally, Millennium Management LLC bought a new position in shares of CapsoVision in the 4th quarter worth $163,000.

Analysts Set New Price Targets

Separately, Benchmark cut their price objective on CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.50.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.